Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

NCT06617325 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT06617325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06617325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Lead sponsor
UCB Biopharma SRL
Phase
Phase 3
Overall status
Recruiting
Start date
November 21, 2024
Completion date
May 31, 2028
Enrollment
450 (estimated)
Sites
242

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus